RecruitingNot Applicable

Cryoablation vs Thoracoscopic Surgery for GGN

China160 participantsStarted 2025-04-20

Plain-language summary

The aim of this study is to investigate the efficacy and safety of Cryoablation and Thoracoscopic Surgery in the treatment of pulmonary ground-glass nodules.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients ≥ 18 years old.
✓. The size of the GGN is 8-20mm (with less than 25% solid component), and the number of nodules requiring treatment in the short term is less than 3.
✓. Pathological confirmation of the GGN as non-small cell lung cancer; or progression of the GGN during at least 3 months of follow-up, including enlargement of the largest diameter, increase in solid component, or the appearance of a significant solid component in a previously pure GGN, with multidisciplinary discussion (including radiology, thoracic surgery, and pulmonology) suggesting malignancy.
✓. No lymph node, pulmonary, or distant metastasis to other organs.
✓. After multidisciplinary evaluation, the patient is considered capable of tolerating both surgical and ablation procedures.
✓. Unsuitable for radiation therapy or refusal of radiation therapy.
✓. Willing to participate in this clinical study and sign the informed consent form.

Exclusion criteria

✕. Patients in poor general condition, with ECOG physical fitness score \>2, unable to tolerate surgery or ablation therapy, or with relevant contraindications.
✕. Patients who have previously received other treatments for pulmonary GGNs.
✕. Patients with poor compliance.
✕. Severe heart, lung, kidney, brain, or other vital organ diseases.
✕. Active bacterial or fungal infections.
✕. Simultaneous or metachronous (within the past 5 years) double cancers.
✕. Women during pregnancy or breast-feeding.
✕. History of radiation therapy.

What they're measuring

2-year disease-free survival

Timeframe: Up to 2 years

Trial details

NCT IDNCT06848881

SponsorShanghai Chest Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-04-15

Contact for this trial

Jiayuan Sun, MD, PhD

+86-021-22200000 xkyyjysun@163.com

View on ClinicalTrials.gov More Ground-Glass Opacity trials